Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial, Efficacy and Safety Study of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea ( Liver qi Affecting the Spleen Pattern)

NCT06753890 is registered in ClinicalTrials.gov with Tasly Pharmaceutical Group Co., Ltd as lead sponsor.

NCT NCT06753890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06753890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial, Efficacy and Safety Study of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea ( Liver qi Affecting the Spleen Pattern)
Lead sponsor
Tasly Pharmaceutical Group Co., Ltd
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 30, 2024
Completion date
December 30, 2026
Enrollment
520 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

diarrhea-predominant irritable boewl syndrome